Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.

Autor: Mariotto S; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy. sara.mariotto@gmail.com.; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. sara.mariotto@gmail.com., Ferrari S; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Monaco S; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Benedetti MD; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Schanda K; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Alberti D; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Farinazzo A; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Capra R; Multiple Sclerosis Centre, Spedali Civili of Brescia, Montichiari, Brescia, Italy., Mancinelli C; Multiple Sclerosis Centre, Spedali Civili of Brescia, Montichiari, Brescia, Italy., De Rossi N; Multiple Sclerosis Centre, Spedali Civili of Brescia, Montichiari, Brescia, Italy., Bombardi R; Neurology Unit, St Bassano Hospital, Bassano del Grappa, Vicenza, Italy., Zuliani L; Neurology Unit, ULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, Italy., Zoccarato M; Neurology Unit, O.S.A, Padua, Italy., Tanel R; Neurology Unit, S. Chiara Hospital, Trento, Italy., Bonora A; Ophthalmology Unit, AOUI Verona, Verona, Italy., Turatti M; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Calabrese M; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy., Polo A; Neurology Unit, Mater Salutis Hospital, Legnago, Verona, Italy., Pavone A; Neurology Unit, Garibaldi Hospital, Catania, Italy., Grazian L; Pediatric Unit, ULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, Italy., Sechi G; Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy., Sechi E; Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy., Urso D; Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy., Delogu R; Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy., Janes F; Neurology Unit, Department of Neuroscience, ASUIUD, Udine, Italy., Deotto L; Neurology A Unit, AOUI Verona, Verona, Italy., Cadaldini M; Multiple Sclerosis Centre of Este, Padua, Italy., Bianchi MR; Neurology Unit, AAS2 Bassa Friulana-Isontina, Gorizia, Italy., Cantalupo G; Child Neurology, University of Verona, Verona, Italy., Reindl M; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Gajofatto A; Department of Neuroscience, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2017 Dec; Vol. 264 (12), pp. 2420-2430. Date of Electronic Publication: 2017 Oct 23.
DOI: 10.1007/s00415-017-8635-4
Abstrakt: Anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) recently emerged as a potential biomarker in patients with inflammatory demyelinating diseases of the central nervous system. We here compare the clinical and laboratory findings observed in a cohort of MOG-Ab seropositive and seronegative cases and describe IgG subclass analysis results. Consecutive serum samples referred to Verona University Neuropathology Laboratory for aquaporin-4 (AQP4)-Ab and/or MOG-Ab testing were analysed between March 2014 and May 2017. The presence of AQP4-Ab was determined using a cell-based assay. A live cell immunofluorescence assay was used for the detection of MOG-IgG and IgG subclass analysis. Among 454 analysed samples, 29 were excluded due to AQP4-Ab positivity or to the final demonstration of a disorder not compatible with MOG-Ab. We obtained clinical data in 154 out of 425 cases. Of these, 22 subjects resulted MOG-Ab positive. MOG-Ab positive patients were mainly characterised by the involvement of the optic nerve and/or spinal cord. Half of the cases presented relapses and the recovery was usually partial. Brain MRI was heterogeneous while short lesions were the prevalent observation on spinal cord MRI. MOG-Ab titre usually decreased in non-relapsing cases. In all MOG-IgG positive cases, we observed IgG1 antibodies, which were predominant in most subjects. IgG2 (5/22), IgG3 (9/22) and IgG4 (3/22) antibodies were also detectable. We confirm that MOG-Ab-related syndromes have distinct features in the spectrum of demyelinating conditions, and we describe the possible role of the different IgG subclasses in this condition.
Databáze: MEDLINE
Externí odkaz: